Drug Profile
Research programme: dopamine D1 receptor agonists - Takeda
Latest Information Update: 16 Jan 2019
Price :
$50
*
At a glance
- Originator CeNeS Pharmaceuticals
- Class
- Mechanism of Action Dopamine D1 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Parkinson's disease
Most Recent Events
- 08 Jan 2019 Shire has been acquired and merged into Takeda
- 29 Aug 2007 No development reported - Preclinical for Parkinson's disease in United Kingdom (unspecified route)
- 19 Sep 2002 Preclinical trials in Parkinson's disease in United Kingdom (unspecified route)